Luke R Johnston1, Carlos J Rodriguez1, Eric A Elster1,2, Matthew J Bradley1,2,3. 1. Department of Surgery, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, Maryland. 2. Surgical Critical Care Initiative, Bethesda, Maryland. 3. Department of Regenerative Medicine, Naval Medical Research Center, Silver Spring, Maryland.
Abstract
Importance: Since publication of the CRASH-2 and MATTERs studies, the US military has included tranexamic acid (TXA) in clinical practice guidelines. While TXA was shown to decrease mortality in trauma patients requiring massive transfusion, improper administration and increased risk of venous thromboembolism remain a concern. Objective: To determine the appropriateness of TXA administration by US military medical personnel based on current Joint Trauma System clinical practice guidelines and to determine if TXA administration is associated with venous thromboembolism. Design, Setting, and Participants: This cohort study of US military casualties in US military combat support hospitals in Afghanistan and a single US-based tertiary military treatment facility within the continental United States was conducted from 2011 to 2015, with follow-up through initial hospitalization and readmissions. Exposures: Data collected for all patients included demographic information as well as Injury Severity Score; receipt of blood products, TXA, and/or a massive transfusion; and admission hemodynamics. Main Outcomes and Measures: Variance from guidelines in TXA administration and venous thromboembolism. Tranexamic acid overuse was defined as a hemodynamically stable patient receiving TXA but not a massive transfusion, underuse was defined as a patient receiving a massive transfusion but not TXA, and TXA administration was considered delayed when given more than 3 hours after injury. Results: Of the 455 identified patients, 443 (97.4%) were male, and the mean (SD) age was 25.3 (4.8) years. A total of 173 patients (38.0%) received a massive transfusion, and 139 (30.5%) received TXA in theater. Overuse occurred in 18 of 282 patients (6.4%) and underuse in 46 of 173 (26.6%) receiving massive transfusions, and delayed administration was found in 6 of 145 patients (4.3%) receiving TXA. Overuse increased at 3.3% per quarter (95% CI, 4.0-9.9; P < .001; R2 = 0.340) and underuse decreased at -4.4% per quarter (95% CI, -4.5 to -3.6; P < .001; R2 = 0.410). Tranexamic acid administration was an independent risk factor for venous thromboembolism (odds ratio, 2.58; 95% CI, 1.20-5.56; P = .02). Conclusions and Relevance: Military medical personnel decreased missed opportunities to appropriately use TXA but also increased overuse. In addition, TXA administration was an independent risk factor for venous thromboembolism. A reevaluation of the use of TXA in combat casualties should be undertaken.
Importance: Since publication of the CRASH-2 and MATTERs studies, the US military has included tranexamic acid (TXA) in clinical practice guidelines. While TXA was shown to decrease mortality in traumapatients requiring massive transfusion, improper administration and increased risk of venous thromboembolism remain a concern. Objective: To determine the appropriateness of TXA administration by US military medical personnel based on current Joint Trauma System clinical practice guidelines and to determine if TXA administration is associated with venous thromboembolism. Design, Setting, and Participants: This cohort study of US military casualties in US military combat support hospitals in Afghanistan and a single US-based tertiary military treatment facility within the continental United States was conducted from 2011 to 2015, with follow-up through initial hospitalization and readmissions. Exposures: Data collected for all patients included demographic information as well as Injury Severity Score; receipt of blood products, TXA, and/or a massive transfusion; and admission hemodynamics. Main Outcomes and Measures: Variance from guidelines in TXA administration and venous thromboembolism. Tranexamic acid overuse was defined as a hemodynamically stable patient receiving TXA but not a massive transfusion, underuse was defined as a patient receiving a massive transfusion but not TXA, and TXA administration was considered delayed when given more than 3 hours after injury. Results: Of the 455 identified patients, 443 (97.4%) were male, and the mean (SD) age was 25.3 (4.8) years. A total of 173 patients (38.0%) received a massive transfusion, and 139 (30.5%) received TXA in theater. Overuse occurred in 18 of 282 patients (6.4%) and underuse in 46 of 173 (26.6%) receiving massive transfusions, and delayed administration was found in 6 of 145 patients (4.3%) receiving TXA. Overuse increased at 3.3% per quarter (95% CI, 4.0-9.9; P < .001; R2 = 0.340) and underuse decreased at -4.4% per quarter (95% CI, -4.5 to -3.6; P < .001; R2 = 0.410). Tranexamic acid administration was an independent risk factor for venous thromboembolism (odds ratio, 2.58; 95% CI, 1.20-5.56; P = .02). Conclusions and Relevance: Military medical personnel decreased missed opportunities to appropriately use TXA but also increased overuse. In addition, TXA administration was an independent risk factor for venous thromboembolism. A reevaluation of the use of TXA in combat casualties should be undertaken.
Authors: Tara N Hutchison; Chad A Krueger; John S Berry; James K Aden; Stephen M Cohn; Christopher E White Journal: J Surg Res Date: 2013-11-15 Impact factor: 2.192
Authors: Haleema Shakur; Ian Roberts; Raúl Bautista; José Caballero; Tim Coats; Yashbir Dewan; Hesham El-Sayed; Tamar Gogichaishvili; Sanjay Gupta; Jorge Herrera; Beverley Hunt; Pius Iribhogbe; Mario Izurieta; Hussein Khamis; Edward Komolafe; María-Acelia Marrero; Jorge Mejía-Mantilla; Jaime Miranda; Carlos Morales; Oluwole Olaomi; Fatos Olldashi; Pablo Perel; Richard Peto; P V Ramana; R R Ravi; Surakrant Yutthakasemsunt Journal: Lancet Date: 2010-06-14 Impact factor: 79.321
Authors: Ian Roberts; Haleema Shakur; Adefemi Afolabi; Karim Brohi; Tim Coats; Yashbir Dewan; Satoshi Gando; Gordon Guyatt; B J Hunt; Carlos Morales; Pablo Perel; David Prieto-Merino; Tom Woolley Journal: Lancet Date: 2011-03-26 Impact factor: 79.321
Authors: Thomas Paffrath; Arasch Wafaisade; Rolf Lefering; Christian Simanski; Bertil Bouillon; Timo Spanholtz; Sebastian Wutzler; Marc Maegele Journal: Injury Date: 2010-01 Impact factor: 2.586
Authors: Karim Brohi; Mitchell J Cohen; Michael T Ganter; Michael A Matthay; Robert C Mackersie; Jean-François Pittet Journal: Ann Surg Date: 2007-05 Impact factor: 12.969
Authors: Sara Juliana de A de Vasconcellos; Edmundo M do Nascimento-Júnior; Marcel Vinícius de Aguiar Menezes; Mário Luis Tavares Mendes; Rafael de Souza Dantas; Paulo Ricardo Saquete Martins-Filho Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-09-01 Impact factor: 6.223
Authors: M Margaret Knudson; Ernest E Moore; Lucy Z Kornblith; Amy M Shui; Scott Brakenridge; Brandon R Bruns; Mark D Cipolle; Todd W Costantini; Bruce A Crookes; Elliott R Haut; Andrew J Kerwin; Laszlo N Kiraly; Lisa M Knowlton; Matthew J Martin; Michelle K McNutt; David J Milia; Alicia Mohr; Ram Nirula; Fredrick B Rogers; Thomas M Scalea; Sherry L Sixta; David A Spain; Charles E Wade; George C Velmahos Journal: JAMA Surg Date: 2022-02-09 Impact factor: 16.681
Authors: Anirban Banerjee; Christopher C Silliman; Ernest E Moore; Monika Dzieciatkowska; Marguerite Kelher; Angela Sauaia; Kenneth Jones; Michael P Chapman; Eduardo Gonzalez; Hunter B Moore; Angelo D'Alessandro; Erik Peltz; Benjamin E Huebner; Peter Einerson; James Chandler; Arsen Ghasabayan; Kirk Hansen Journal: J Trauma Acute Care Surg Date: 2018-06 Impact factor: 3.313
Authors: Francis X Guyette; Joshua B Brown; Mazen S Zenati; Barbara J Early-Young; Peter W Adams; Brian J Eastridge; Raminder Nirula; Gary A Vercruysse; Terence O'Keeffe; Bellal Joseph; Louis H Alarcon; Clifton W Callaway; Brian S Zuckerbraun; Matthew D Neal; Raquel M Forsythe; Matthew R Rosengart; Timothy R Billiar; Donald M Yealy; Andrew B Peitzman; Jason L Sperry Journal: JAMA Surg Date: 2020-10-05 Impact factor: 14.766
Authors: Adam Miszta; Homa K Ahmadzia; Naomi L C Luban; Shuhui Li; Dong Guo; Lori A Holle; Jeffrey S Berger; Andra H James; Jogarao V S Gobburu; John van den Anker; Bas de Laat; Alisa S Wolberg Journal: J Thromb Haemost Date: 2020-12-26 Impact factor: 5.824